- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06083012
Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation (COMRADE-AI)
November 21, 2023 updated by: Volta Medical
The goal of this Observational Prospective Multi-center Study is to observe the acute and long-term safety and performance outcomes after spatiotemporal dispersion-based AF/AT ablation utilizing the Volta Medical AI software in "real-life" clinical practice, without any imposed clinical workflow.
Moreover, this study will allow to collect medico-economic data related to the tailored ablation strategy guided by the Volta Medical AI software.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
All patients enrolled are treated for atrial fibrillation/tachycardia via a catheter ablation procedure using Volta Medical AI software during the mapping phase to identify areas of interest specific to the patient.
The ablation approach is free and chosen by the operator according to standard practice.
Intraoperative and postoperative follow-up will be performed as in routine clinical practice during AF ablation procedures: hospitalization for ablation procedure and standard postoperative quarterly visits (at 3 months, at 6 months and/or 9 months as per the study investigator's Standard Of Care) then annual visits up to 24 months post-ablation.
Adverse Events, recurrences of atrial arrhythmia and AF related symptoms (EHRA score) are collected from the patient's enrollment until the patient's study termination.
A quality-of-life questionnaire related to general health (EQ-5D-3L) is collected during the preoperative visit and at least during annual follow-up visits.
The patient's study-termination corresponds to the last annual visit at 24 months post-ablation index.
Study Type
Observational
Enrollment (Estimated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Paola MILPIED
- Phone Number: +33768025499
- Email: paola.milpied@volta-medical.com
Study Contact Backup
- Name: Alexandra SANS
- Email: alexandra.sans@volta-medical.com
Study Locations
-
-
-
Marseille, France, 13008
- Recruiting
- Hôpital Saint-Joseph
-
Contact:
- Julien SEITZ, MD
- Email: jseitz@hopital-saint-joseph.fr
-
Toulouse, France, 31000
- Recruiting
- Clinique Pasteur
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All adult patient candidate eligible for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using VX1.
Description
Inclusion Criteria:
- Patient aged 18 years or older.
- Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using VX1.
- Patient able and willing to provide written informed consent to participate in the study.
- Only for France: Patient affiliated to the French social security system.
Exclusion Criteria:
- Contraindication to AF/AT catheter ablation.
- Patient who is or could potentially be pregnant.
- Person deprived of liberty or under guardianship.
- Person unable to undergo a medical monitoring for geographical, social or psychological reasons.
- Patient's refusal to participate in the study.
- Enrollment in an investigational study evaluating another device, biologic, or drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Freedom from clinically significant AF or atrial arrhythmia recurrence, after one or multiple ablation procedures, with or without antiarrhythmic drugs, stratified by type of clinical workflow.
Time Frame: [24 months]
|
[24 months]
|
VX1-related Incident rate during ablation procedure.
Time Frame: [24months]
|
[24months]
|
VX1-related Adverse Event rate.
Time Frame: [24months]
|
[24months]
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression of Quality-Of-Life score ("EQ-5D-3L") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
Time Frame: Preoperative; [24months]
|
Preoperative; [24months]
|
Progression of the AF related symptom score ("EHRA") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
Time Frame: Preoperative; [24months]
|
Preoperative; [24months]
|
Hospitalization rate during the post-ablation follow-up period.
Time Frame: [24months]
|
[24months]
|
Serious Adverse Event rate during the post-ablation follow-up period.
Time Frame: [24months]
|
[24months]
|
Average number of ablation procedures per patient up to 24 months follow-up.
Time Frame: [24months]
|
[24months]
|
Average number of cardioversions per patient up to 24 months follow-up
Time Frame: [24months]
|
[24months]
|
Progression of patient proportion under antiarrhythmic drugs and/or anticoagulant treatments during the study.
Time Frame: [24months]
|
[24months]
|
Health economics analysis including QALY metric.
Time Frame: [24months]
|
[24months]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Julien SEITZ, MD, Hôpital Saint Joseph Marseille
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Seitz J, Bars C, Theodore G, Beurtheret S, Lellouche N, Bremondy M, Ferracci A, Faure J, Penaranda G, Yamazaki M, Avula UM, Curel L, Siame S, Berenfeld O, Pisapia A, Kalifa J. AF Ablation Guided by Spatiotemporal Electrogram Dispersion Without Pulmonary Vein Isolation: A Wholly Patient-Tailored Approach. J Am Coll Cardiol. 2017 Jan 24;69(3):303-321. doi: 10.1016/j.jacc.2016.10.065.
- Seitz J, Durdez TM, Albenque JP, Pisapia A, Gitenay E, Durand C, Monteau J, Moubarak G, Theodore G, Lepillier A, Zhao A, Bremondy M, Maluski A, Cauchemez B, Combes S, Guyomar Y, Heuls S, Thomas O, Penaranda G, Siame S, Appetiti A, Milpied P, Bars C, Kalifa J. Artificial intelligence software standardizes electrogram-based ablation outcome for persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2022 Nov;33(11):2250-2260. doi: 10.1111/jce.15657. Epub 2022 Sep 18.
- Deisenhofer I. Electrogram-based AF ablation: finally, reproducibility! J Cardiovasc Electrophysiol. 2022 Nov;33(11):2261-2262. doi: 10.1111/jce.15660. Epub 2022 Sep 18. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 27, 2023
Primary Completion (Estimated)
October 27, 2026
Study Completion (Estimated)
October 27, 2026
Study Registration Dates
First Submitted
October 9, 2023
First Submitted That Met QC Criteria
October 9, 2023
First Posted (Actual)
October 13, 2023
Study Record Updates
Last Update Posted (Actual)
November 27, 2023
Last Update Submitted That Met QC Criteria
November 21, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIPL-01-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on Cardiac mapping
-
Biosense Webster, Inc.TerminatedParoxysmal Atrial FibrillationCanada
-
University Hospital Center of MartiniqueGIRCI SOHONot yet recruitingCardiac Disease | Cardiac AmyloidosisMartinique
-
University Hospital, BordeauxCompletedAtrial Fibrillation | Ventricular Fibrillation | Junctional TachycardiaFrance
-
Abbott Medical DevicesCompleted
-
The Hospital for Sick ChildrenCompleted
-
Chinese University of Hong KongRecruiting
-
Chinese University of Hong KongRecruiting
-
Chinese University of Hong KongRecruiting
-
Oxford University Hospitals NHS TrustCompletedAtrial FibrillationUnited Kingdom
-
University Hospital, Basel, SwitzerlandMedtronic; Freiwillige Akademische Gesellschaft (FAG) BaselRecruitingNew-onset Atrial Fibrillation (NOAF)Switzerland